Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Recommendation of “Hold” from Brokerages

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Free Report) has been given an average rating of “Hold” by the twenty-one ratings firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $420.48.

A number of brokerages have recently issued reports on VRTX. Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research note on Wednesday, January 31st. Truist Financial boosted their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Finally, Wolfe Research started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective on the stock.

Check Out Our Latest Report on Vertex Pharmaceuticals

Insider Buying and Selling

In related news, Chairman Jeffrey M. Leiden sold 6,648 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the transaction, the chairman now owns 2,423 shares of the company’s stock, valued at $1,015,406.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 6,648 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the sale, the chairman now directly owns 2,423 shares of the company’s stock, valued at approximately $1,015,406.61. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,029 shares of company stock valued at $7,989,227. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at $25,000. University of Texas Texas AM Investment Managment Co. bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $25,000. ST Germain D J Co. Inc. bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at $26,000. Arlington Trust Co LLC boosted its stake in Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the last quarter. Finally, ICA Group Wealth Management LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $28,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 0.2 %

NASDAQ VRTX opened at $418.01 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The firm has a market cap of $107.98 billion, a PE ratio of 30.09, a P/E/G ratio of 2.28 and a beta of 0.35. Vertex Pharmaceuticals has a one year low of $310.90 and a one year high of $448.40. The firm’s fifty day moving average is $422.13 and its two-hundred day moving average is $392.05.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the business posted $3.33 earnings per share. Analysts expect that Vertex Pharmaceuticals will post 14.95 earnings per share for the current year.

About Vertex Pharmaceuticals

(Get Free Report

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.